Press Releases Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Delayed London S.E. Other stock markets 05:04:55 17/02/2026 pm IST			5-day change	1st Jan Change
57.00 ^GBX	+2.70%		-4.20%	-1.72%

09/02	Avacta appoints new chief scientific officer, plans clinical trials	AN
09/02	Avacta Therapeutics Names Chemistry Vice President as Chief Scientific Officer	MT

Press Releases

13/02	Avacta : Academy – Episode 1	PU
09/02	Avacta appoints Francis Wilson as Chief Scientific Officer	GL
09/02	Avacta appoints Francis Wilson as Chief Scientific Officer	AQ
03/02	Avacta Announces Two Key Clinical Updates to its Faridoxorubicin Program	GL
21/01	Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre\|CISION® Medicine, FAP-Exatecan (AVA6103)	GL
20/01	Avacta Announces Year-end Trading Update	GL
18/12	Avacta : Research & Development Spotlight Series, Episode 13	PU
17/12	Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers	GL
17/12	Avacta : Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers	PU
27/25/27	Avacta presents first preclinical data from dual payload pre, CISION medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets	AQ
25/25/25	Avacta presents first preclinical data from dual payload pre\|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets	GL
21/25/21	Avacta : ESMO Phase 1a data for faridoxorubicin presented by Chris Coughlin and David Liebowitz	PU
20/25/20	Avacta : Equity fundraise of £16 million	PU
19/25/19	Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre\|CISION® Platform at the European Society of Medical Oncology Annual Congress	GL
13/25/13	Avacta to Present First Dual Payload pre\|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium	GL
13/25/13	Avacta : Research & Development Spotlight Series, Episode 12	PU
13/25/13	Avacta : to Present First Dual Payload pre\|CISION® Medicines Data at the 2025 EORTC-NCI-AACR International Conference on Molecular Targets Symposium	PU
01/25/01	Avacta : Research & Development Spotlight Series, Episode 11	PU
30/25/30	Avacta : Interim Results for the six months to June 30, 2025	PU
30/25/30	Avacta to Present New FAP Dox (AVA6000) Data at the European Society for Medical Oncology (ESMO) Congress	GL
24/25/24	Avacta : Corporate Deck – July 2025	PU
03/25/03	Avacta Group plc - Result of AGM	AQ
02/25/02	Avacta : AGM Business Update deck 2025	PU
01/25/01	Avacta Appoints David Liebowitz, M.D., Ph.D. as Chief Medical Officer and Yulii Bogatyrenko as Advisor in Business Development	GL
30/25/30	Avacta : Appointment of Zeus Capital as Joint Broker to Avacta Group plc	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages MarketScreener Editorial Features MarketScreener Strategies Trading Ideas

Press Releases Avacta Group Plc

Equities

AVCT

GB00BYYW9G87

Biotechnology & Medical Research

Press Releases

Filters